US Medical Devices Market Outlook to 2030

Healthcare Expenditure and Procedure Recovery

• Hospital spending increased 8.9% to USD 1.63 trillion (2024, United States), supporting equipment replacement, monitoring systems, surgical capacity, imaging installations, and higher-value clinical workflows.
• Physician and clinical services expenditure increased 8.1% to USD 1.11 trillion (2024, United States), expanding demand across specialty practices, office-based laboratories, diagnostics, and minimally invasive procedures.
• Approximately 6,400 ASCs treated 3.4 million Medicare beneficiaries (2024, United States), shifting device purchasing toward compact platforms, procedure-specific kits, rapid setup, and lower service complexity.

Regulatory Throughput and Product Innovation

• 44 breakthrough-designated devices received marketing authorization (2025, United States), supporting premium clinical categories where manufacturers can demonstrate material improvements over established care pathways.
• FDA received 21,780 medical-device submissions (2025, United States), indicating a broad pipeline of product modifications, new technologies, and regulatory activity across multiple risk classes.
• The Total Product Life Cycle Advisory Program enrolled 108 devices with 98% participant satisfaction (2025, United States), helping innovators clarify evidence, access, and commercialization requirements earlier.

Chronic Disease and Long-Term Monitoring Demand

• Approximately 20.5 million adults have coronary heart disease (latest official estimate, United States), sustaining demand for diagnostic imaging, interventional cardiology, rhythm management, and post-procedure monitoring.
• About 6.7 million adults have heart failure (latest official estimate, United States), supporting implantable monitoring, remote patient management, ventricular-assist, imaging, and therapeutic-device demand.
• Medical-device manufacturers can capture recurring revenue through sensors, consumables, software subscriptions, replacement components, and service contracts rather than relying exclusively on one-time equipment sales.

Quality-System Transition and Compliance Cost

• FDA oversight covered 25,530 registered manufacturing firms (2025, United States), creating substantial industry-wide requirements for documentation, supplier controls, risk management, corrective actions, and inspection readiness.
• FDA replaced the Quality System Inspection Technique with compliance program 7382.850 in February 2026, requiring organizations to update internal audit frameworks and inspection preparation.
• Smaller manufacturers face disproportionate fixed costs because validation, training, electronic records, supplier remediation, and consultant expenditure must be absorbed across narrower product portfolios.

Cybersecurity and Connected-Device Liability

• FDA's June 2025 cybersecurity guidance addresses design, labeling, quality-system controls, and premarket documentation for devices with cybersecurity risk, raising development and evidence requirements.
• Connected devices require vulnerability monitoring, coordinated disclosure, update capability, component inventories, threat modeling, authentication, and secure software-development practices throughout the supported product life.
• Manufacturers unable to fund long-term software support face higher recall, remediation, litigation, hospital-procurement, and reputational risk, particularly when products remain clinically deployed for many years.

Trade and Supply-Chain Exposure

• US medtech exports averaged approximately USD 72 billion during 2022-2024, making foreign regulatory access, customs policy, and international reimbursement important to manufacturing scale.
• Semiconductors, specialty polymers, electronic components, sterilization services, precision metals, batteries, and rare materials can create single-source dependencies that are difficult to substitute after regulatory validation.
• Manufacturers must balance dual sourcing and domestic resilience against revalidation expense, inventory requirements, supplier qualification, and lower purchasing leverage across fragmented component volumes.

AI-Enabled Diagnostic and Therapeutic Devices

• Manufacturers can combine device sales with software subscriptions, algorithm upgrades, analytics, workflow modules, cloud hosting, and outcome-oriented service agreements.
• Imaging manufacturers, diagnostic laboratories, health systems, software developers, cloud partners, and investors benefit from recurring digital revenue and faster clinical interpretation.
• Developers require representative data, predetermined change protocols, real-world monitoring, cybersecurity controls, human oversight, and transparent performance governance before scaled adoption.

Ambulatory and Office-Based Procedure Platforms

• Compact capital systems, procedure kits, leasing, managed equipment, per-case pricing, maintenance, and physician-training services address ASC capital and staffing constraints.
• Surgical-device companies, distributors, private-equity-backed physician platforms, specialty practices, and patients benefit from lower-complexity settings and standardized procedure pathways.
• Products must offer smaller footprints, rapid turnover, simplified sterilization, predictable consumable costs, remote service, and training suitable for leaner clinical teams.

Remote Monitoring and Home-Based Care

• Remote monitoring supports device subscriptions, disposable sensors, patient engagement software, clinical dashboards, maintenance, connectivity, and reimbursement-linked service models.
• Chronic-care patients, home-health providers, health systems, Medicare plans, device manufacturers, and virtual-care operators benefit from longitudinal data and earlier intervention.
• Adoption requires interoperable data, reliable connectivity, simple patient setup, clinical workflow integration, alert prioritization, cybersecurity, and reimbursement models aligned with measurable outcomes.

Government & Regulators

International Institutions

Trade & Industry Bodies

Company Filings

Key Assumptions

• Domestic market value reflects revenue attributable to devices and device-linked services purchased by US end users.
• Export revenue is removed to prevent foreign customer expenditure from entering the domestic estimate.
• Imported medical devices purchased by US customers are included irrespective of manufacturer headquarters.
• Hospital services, pharmaceuticals, general consumer electronics, and standalone health IT are excluded.
• In-vitro diagnostics are included where revenue relates to regulated analyzers, instruments, testing devices, and associated reagents.
• Device software is included where it is regulated as a device or materially integrated with a regulated device platform.
• Company shares represent estimated US medical-device revenue rather than global consolidated company revenue.
• Volume is represented by a weighted index because product categories use non-comparable physical units.

Forecast Boundaries

• The base scenario assumes continued healthcare expenditure growth, stable procedural demand, and gradual hospital-capital replacement.
• The forecast incorporates QMSR compliance costs without assuming a structural reduction in device availability.
• No prolonged nationwide disruption to hospital procedures, sterilization capacity, or critical component supply is assumed.
• Connected and AI-enabled device adoption progresses alongside cybersecurity, clinical validation, and reimbursement development.
• Pricing, premium product mix, software, consumables, and service contracts are incorporated into the ASP and product-mix index.
• Forecast values exclude acquisitions that merely transfer revenue between existing market participants.
• The forecast CAGR reconciles with the 2025 and 2031 modeled market values.

Limitations

• Multinational manufacturers frequently disclose regional revenue rather than precise US product-level revenue.
• Private-company revenue, distributor margins, and device-linked software revenue require benchmark-based estimation.
• Medical-device categories use heterogeneous units, making a standardized physical-volume measure impractical.
• Trade classifications may combine regulated devices, components, accessories, laboratory products, and adjacent equipment.
• Peer-country estimates are normalized to a consistent scope and should not be compared with differently defined published values.
• Rapid changes in AI regulation, tariffs, reimbursement, procedure location, and product recalls can alter category-level forecasts.